Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS]

August 6, 2026

Company Name: PHC HOLDINGS CORPORATION
Stock Code: 6523 (URL: https://www.phchd.com/global/ir)
Stock Exchange Listing: Tokyo
Representative: Kyoko Deguchi, Chief Executive Officer
Contact: Masashi Kimura, Executive General Manager of Corporate Administration Department
Phone: +81-3-5408-7280
Scheduled date to commence dividend payments: －
Availability of supplementary briefing material on the First Quarter results: Yes
Scheduled date of the First Quarter Results Briefing Session: Yes

(Figures are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (From April 1, 2026 to June 30, 2026)

(1) Consolidated Results of Operations

(% indicates changes from the previous corresponding term)

	Revenue		Operating profit		Profit before taxes		Profit		Profit attributable to owners of parent		Comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three Months ended June 30, 2026	90,672	8.1	10,413	171.0	8,133	-	6,293	-	6,338	-	10,119	-
Three Months ended June 30, 2025	83,856	(1.6)	3,843	89.6	(1,990)	-	(2,474)	-	(2,341)	-	(1,330)	-

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three Months ended June 30, 2026	50.06	49.84
Three Months ended June 30, 2025	(18.55)	(18.55)

(Note) Share of profit (loss) of investments accounted for using equity method:
June 30, 2026… (28)million yen
June 30, 2025… (8)million yen

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	543,077	168,468	169,314	31.2
March 31, 2026	542,510	160,880	161,668	29.8

2. Cash dividends

	Annual cash dividends per share				
	First quarter end	Second quarter end	Third quarter end	Fiscal year end	Total
Fiscal year ended	Yen	Yen	Yen	Yen	Yen
March 31, 2026	-	21.00	-	21.00	42.00
March 31, 2027	-				
Fiscal year ending March 31, 2027 (Forecast)		21.00	-	21.00	42.00

(Note) Revision of cash dividends forecasts to the latest announcement: None

3. Forecast of Consolidated Financial Results for the Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

(% indicates year-on-year changes)

	Revenue		Operating profit		Profit before taxes		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2027	359,700	(1.3)	27,000	19.0	22,000	244.3	15,400	-	15,400	-	121.73

(Note) Revision of consolidated earnings forecasts to the latest announcement: None

*** Notes**

(1) Changes in significant subsidiaries during the current period (Changes in specific subsidiaries involving changes in the scope of consolidation): None

Newly included: - companies

Excluded: - companies

(2) Changes in accounting policies, changes in accounting estimates

1) Changes in accounting policies required by IFRS: Not applicable

2) Changes in accounting policies other than 1) : Not applicable

3) Changes in accounting estimates: Not applicable

(3) Total number of issued shares (common stock):

1) Total number of issued shares at the end of the period (including treasury shares):

As of June 30, 2026	127,320,915 Shares
As of March 31, 2026	126,724,020 Shares

2) Total number of treasury shares at the end of the period:

As of June 30, 2026	212,023 Shares
As of March 31, 2026	211,966 Shares

3) Average number of outstanding shares during the period:

Three months ended June 30, 2026	126,619,910 Shares
Three months ended June 30, 2025	126,254,536 Shares

Note 1: Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Note 2: Explanation regarding proper use of the projected financial results and other notes:
The forecasted statements shown in these materials are based on information currently available and certain assumptions that PHC Holdings Corporation regards as reasonable, and therefore the group's actual results may differ materially due to unknown several factors.

Contents of attached documents:

1. Qualitative information regarding financial performance
   (1) Explanation regarding operation results 5
   (2) Explanation regarding financial position 12
   (3) Explanation regarding cash flow 12
   (4) Explanation regarding future prospects (ex. forecasted consolidated business results) 13
2. Condensed consolidated quarterly financial statement and significant notes
   (1) Condensed quarterly consolidated statement of financial position 14
   (2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income 16
   (3) Condensed quarterly consolidated statement of changes in equity 18
   (4) Condensed quarterly consolidated statement of cash flows 20
   (5) Notes to condensed quarterly consolidated financial statements 21
      Notes for going concern 21
      Segment information 21
      Revenue 23

1. Qualitative information regarding financial performance

(1) Explanation regarding operation results

Please note that some of our business names and segment classifications have been changed from the three months ended June 30, 2026 (hereafter “this period”). BGM business in “Diabetes Management” segment has been renamed “Diabetes Management business”, while LSIM business in “Healthcare Solutions” segment has been renamed “Clinical Testing business”. In addition, Biomedical business and IVD business within “Diagnostics & Life Sciences” segment have been integrated into “Life Sciences business”. Furthermore, the B-to-B business in Indonesia, previously included in “Others” has been transferred to “Diagnostics & Life Sciences” and included in “Life Sciences business”. The following descriptions reflect these revised classifications, and segment information for the previous period has restated accordingly.

During this period, PHC Group generated revenue of JPY 90,672 million, up 8.1% compared to the same period of the previous year (hereafter “year on year”). In Diabetes Management, revenue increased mainly due to strong sales and the positive impact of foreign exchange despite ongoing market decline and the shift to low-priced channels in developed countries. In Healthcare Solutions, despite lower revenue in Healthcare IT Solutions business, revenue increased mainly due to higher volumes of general testing and sales growth in genetic testing as a growth initiative in Clinical Testing business, and increased orders in CRO business. In Diagnostics & Life Sciences, revenue increased due to solid consumables sales and the effects of price revisions in Pathology business, solid sales in Asia in Life Sciences business, and favorable foreign exchange effects.

Operating profit for this period was JPY 10,413 million, up 171.0% year on year. In Diabetes Management, operating profit increased significantly due to strong sales, cost reductions, improved profit margins following the transfer of the Continuous Glucose Monitoring (hereafter "CGM") business, and the positive impact of foreign exchange. In Healthcare Solutions, operating profit increased mainly due to higher revenue in Clinical Testing business and CRO business, as well as cost reduction initiatives. Diagnostics & Life Sciences saw an increase in operating profit primarily because of price revisions, lower SG&A expenses, and the impact of U.S. tariffs refunds.

Adjusted EBITDA was JPY 17,253 million, up 58.1% year on year. Adjustment items include one-time income/expense relating to restructuring (additions of JPY 137 million in this period and JPY 368 million in the same period of the previous fiscal year, hereafter “the previous period”) and one-time income/expense relating to transformational M&A pre-acquisition and integration costs (additions of JPY 61 million in this period and JPY 36 million in the previous period, respectively).

Profit before tax was JPY 8,133 million (loss of JPY 1,990 million in the previous period). This was mainly due to the increase in operating profit and a decrease in foreign exchange losses.

Profit attributable to owners of parent was JPY 6,338 million (loss of JPY 2,341 million in the previous period).

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Revenue	83,856	90,672	8.1%
Operating profit	3,843	10,413	171.0%
EBITDA	10,506	17,075	62.5%
Adjusted EBITDA	10,911	17,253	58.1%
Profit (loss) before tax	(1,990)	8,133	―
Profit (loss)	(2,474)	6,293	―
Profit (loss) attributable to owners of parent	(2,341)	6,338	―
Average exchange rate JPY/USD	JPY 144.46	JPY 159.40	JPY 14.94
Average exchange rate JPY/EUR	JPY 163.86	JPY 185.28	JPY 21.42

(Note) EBITDA and Adjusted EBITDA are not measures in accordance with IFRS. However, PHC Holdings Corporation believes that this disclosure may be useful information to investors.

【Calculation table of EBITDA and adjusted EBITDA】

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Operating profit	3,843	10,413	171.0%
+ Depreciation	6,661	6,691	0.5%
+ Impairment loss (excluding marketable securities)	1	(28)	―
EBITDA	10,506	17,075	62.5%
(Adjusted amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	36	61	69.4%
+ One-time income/expense relating to restructuring	368	137	(62.8%)
+ One-time income/expense relating to termination/cancellation of contracts	―	(20)	―
+ Other one-time income/expense	―	―	―
Adjusted EBITDA	10,911	17,253	58.1%

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:
EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)
Adjusted EBITDA = EBITDA + one-time income and expenses

The business performance by segment is as follows:

Diabetes Management

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Revenue	23,137	27,814	20.2%
Operating profit	3,953	9,180	132.2%
EBITDA	5,043	10,295	104.1%
Adjusted EBITDA	5,160	10,353	100.6%

(Calculation table of EBITDA and adjusted EBITDA)

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Operating profit	3,953	9,180	132.2%
+ Depreciation	1,090	1,144	5.0%
+ Impairment loss (excluding marketable securities)	―	(28)	―
EBITDA	5,043	10,295	104.1%
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	―	61	―
+ One-time income/expense relating to restructuring	116	(2)	―
+ One-time income/expense relating to termination/cancellation of contracts	―	―	―
+ Other one-time income/expense	―	―	―
Adjusted EBITDA	5,160	10,353	100.6%

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:
EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)
Adjusted EBITDA = EBITDA + one-time income and expenses

<Revenue Situation>

Revenue of Diabetes Management for this period was JPY 27,814 million, up 20.2% year on year. Despite ongoing market decline and the shift to low-priced channels in developed countries, revenue in BGM business increased due to higher sales volume in the U.S. and strong sales in Europe, particularly in Germany, Italy, and Greece. Revenue in emerging countries increased due to the recovery in the Middle East and progress in localization initiatives in Algeria. Revenue increased significantly year on year with favorable foreign exchange effects and offset the negative impact from the transfer of CGM business.

<Operating Profit and Adjusted EBITDA Situation>

Operating profit in Diabetes Management for this period was JPY 9,180 million, up 132.2% year on year. Operating profit increased significantly due to strong sales in developed countries, as well as revenue growth in emerging markets. In addition, favorable foreign exchange effects, cost reduction with restructuring to date, and improved profitability related to the transfer of CGM business contributed to the substantial increase in profit. Adjusted EBITDA was JPY 10,353 million, up 100.6% year on year. Adjustment items included one-time income/expense relating to transformational M&A pre-acquisition and integration costs (addition of JPY 61 million in this period), attributable to the expenses related to the transfer of CGM business.

Healthcare Solutions

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Revenue	30,474	30,976	1.6%
Operating profit	860	1,097	27.6%
EBITDA	3,492	3,578	2.5%
Adjusted EBITDA	3,529	3,696	4.7%

(Calculation table of EBITDA and adjusted EBITDA)

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Operating profit	860	1,097	27.6%
+ Depreciation	2,632	2,481	(5.7%)
+ Impairment loss (excluding marketable securities)	—	—	—
EBITDA	3,492	3,578	2.5%
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	36	—	—
+ One-time income/expense relating to restructuring	—	117	—
+ One-time income/expense relating to termination/cancellation of contracts	—	—	—
+ Other one-time income/expense	—	—	—
Adjusted EBITDA	3,529	3,696	4.7%

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:
EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)
Adjusted EBITDA = EBITDA + one-time income and expenses

<Revenue Situation>

Revenue of Healthcare Solutions for this period was JPY 30,976 million, up 1.6% year on year. A breakdown includes Clinical Testing business at JPY 17,250 million, up 2.4% year on year, Healthcare IT Solutions business at JPY 11,559 million, down 5.0% year on year, and CRO business at JPY 2,166 million, up 47.4% year on year.

In Clinical Testing business, revenue increased due to higher volumes of general testing, sales growth in genetic testing as a growth initiative, and progress in pricing optimization.

In Healthcare IT Solutions business, revenue decreased due to the decline from the strong replacement demand for electronic medical record and medical-receipt systems in the previous period, despite increased revenue driven by growing demand for electronic prescription software.

In CRO business, revenue increased primarily due to higher orders, in both clinical trial and non-clinical testing businesses in the previous fiscal year, as well as the completion of large-scale safety testing in the non-clinical testing business.

<Operating Profit and Adjusted EBITDA Situation>

Operating profit in Healthcare Solutions for this period was JPY 1,097 million, up 27.6% year on year. Despite the lower revenue in Healthcare IT Solutions business, operating profit increased due to higher revenue in Clinical Testing and CRO businesses, as well as improved profitability driven by mainly progress in pricing optimization and cost reduction efforts.

Adjusted EBITDA was JPY 3,696 million, up 4.7% year on year. Adjustment items include one-time income/expense relating to restructuring (addition of JPY 117 million in this period).

Diagnostics and Life Sciences

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Revenue	30,177	31,797	5.4%
Operating profit	871	1,813	108.2%
EBITDA	3,659	4,688	28.1%
Adjusted EBITDA	3,660	4,691	28.2%

(Calculation table of EBITDA and adjusted EBITDA)

	Three months ended June 30, 2025 (million yen)	Three months ended June 30, 2026 (million yen)	Change
Operating profit	871	1,813	108.2%
+ Depreciation	2,786	2,875	3.2%
+ Impairment loss (excluding marketable securities)	1	—	—
EBITDA	3,659	4,688	28.1%
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	—	—	—
+ One-time income/expense relating to restructuring	0	23	—
+ One-time income/expense relating to termination/cancellation of contracts	—	(20)	—
+ Other one-time income/expense	—	—	—
Adjusted EBITDA	3,660	4,691	28.2%

(Note) 1. The B-to-B business in Indonesia, which was previously in "Others," has been transferred to “Diagnostics and Life Sciences” and classified as “Life Sciences business”. Segment information for the previous period has also been restated to reflect this change.

2. EBITDA and adjusted EBITDA are calculated with the following formulas:
EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)
Adjusted EBITDA = EBITDA + one-time income and expenses

<Revenue Situation>

Revenue of Diagnostics and Life Sciences for this period was JPY 31,797 million, up 5.4% year on year. This includes JPY 14,286 million in Pathology business, up 5.1% year on year, JPY 17,511 million in Life Sciences business, up 5.6% year on year.

In Pathology business, revenue increased year on year, driven by solid consumables sales, the positive effect of price revisions, and favorable foreign exchange effects. On the other hand, equipment sales declined due to slow demand of capital equipment combined with the absence of large-scale projects for digital pathology products recorded in the previous period.

In Life Sciences business, revenue increased mainly due to the positive impact of foreign exchange rates and solid sales of the laboratory and medical support equipment in Japan and Asia. In the Americas, despite delays in large-scale projects for pharmaceutical companies, revenue increased due to higher orders for smaller-scale projects and the positive impact of favorable foreign exchange. In contrast, revenue in EMEA declined as stagnant market conditions in France, Germany, and other countries more than offset favorable foreign exchange effects and the contribution from year-end academic demand in the U.K. In IVD area, revenue increased slightly year on year, as strong sales in EMEA and Asia more than offset lower sales in Americas.

<Operating Profit and Adjusted EBITDA Situation>

Operating profit in Diagnostics and Life Sciences for this period was JPY 1,813 million, up 108.2% year on year. Operating profit increased due to the effects of price revisions, lower SG&A expenses, U.S. tariff refunds, and favorable foreign exchange effects.

Adjusted EBITDA was JPY 4,691 million, up 28.2% year on year. Adjustment items include one-time income/expense relating to restructuring (additions of JPY 23 million in this period and JPY 0 million in the previous period, respectively) and one-time income/expense relating to termination/cancellation of contracts (subtraction of JPY 20 million in this period).

(2) Explanation regarding financial position

Assets

The balance of total assets in this period was JPY 543,077 million. The balance increased by JPY 567 million compared to the previous fiscal year-end.
Main changes are goodwill increased by JPY 1,849 million attributable to the impact of currency fluctuation, and intangible assets decreased by JPY 1,901 million, mainly due to progress in amortization of intangible assets recognized through past business acquisitions.

Liabilities

The balance of total liabilities in this period was JPY 374,609 million. The balance decreased by JPY 7,020 million compared to the previous fiscal year-end.
The main changes are loan balance decreased by JPY 5,294 million mainly due to the repayments, trade and other payables decreased by JPY 4,902 million, and Income taxes payable increased by JPY 1,170 million.

Equity

The balance of equity in this period was JPY 168,468 million. The balance increased by JPY 7,587 million compared to the previous fiscal year-end. Other components of equity increased by JPY 2,921 million, mainly due to translation differences of foreign operations. Retained earnings increased by JPY 4,600 million mainly due to JPY 6,338 million of profit attributable to owners of parent, despite dividends of JPY 2,656 million.
In addition, the ratio of equity attributable to owners of parent to total assets increased by 1.4 points from 29.8% at the end of the previous fiscal year to 31.2%.

(3) Explanation regarding cash flow

Cash and cash equivalents at the end of this period amounted to JPY 41,282 million, reflecting an increase of JPY 1,462 million from March 31, 2026.

The status of cash flows from each activity and its drivers during this period are as follows:

(Cash flows from operating activities)
Net cash provided by operating activities was JPY 14,331 million, which was an increase of JPY 8,948 million year on year. The year on year increase in net cash provided by operating activities was primarily due to increased profit before taxes and decreased income taxes paid.

(Cash flows from investing activities)
Net cash used in investing activities was JPY 3,313 million and consisted mainly of purchase of property, plant, and equipment, and intangible assets of JPY 2,727 million. This represents a year on year increase of JPY 1,248 million in net cash used in investing activities which was primarily due to decreased purchase of property, plant and equipment and intangible assets of JPY 486 million.

(Cash flows from financing activities)
Net cash used in financing activities of JPY 10,018 million consists mainly of repayments of borrowings of JPY 5,958 million and Dividends paid to owners of parent over JPY 2,490 million. The year on year decrease was JPY 528 million.

(4) Explanation regarding future prospects (ex. forecasted consolidated business results)
There is no change from forecasts for consolidated financial results released on May 13, 2026.

2. Condensed consolidated quarterly financial statement and significant notes

(1) Condensed quarterly consolidated statement of financial position

(Unit: million yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	39,820	41,282
Trade receivables	70,283	66,236
Inventories	53,095	55,139
Other financial assets	4,925	4,805
Other current assets	8,055	7,761
Total current assets	176,180	175,225
Non-current assets		
Property, plant and equipment	49,242	48,596
Goodwill	221,524	223,374
Intangible assets	74,371	72,470
Investments accounted for using equity method	730	651
Other financial assets	10,988	10,881
Deferred tax assets	6,482	7,067
Other non-current assets	2,990	4,812
Total non-current assets	366,330	367,852
Total assets	542,510	543,077

(Unit: million yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	72,379	67,529
Borrowings	78,254	78,289
Income taxes payable	2,588	3,759
Provisions	8,234	8,463
Other financial liabilities	5,709	5,802
Other current liabilities	22,467	23,623
Total current liabilities	189,634	187,467
Non-current liabilities		
Trade and other payables	537	485
Borrowings	156,303	150,974
Retirement benefit liability	5,962	5,038
Provisions	4,955	6,590
Other financial liabilities	11,278	11,170
Deferred tax liabilities	11,472	11,782
Other non-current liabilities	1,487	1,101
Total non-current liabilities	191,995	187,141
Total liabilities	381,630	374,609
Equity		
Share capital	48,785	49,114
Capital surplus	42,636	42,430
Retained earnings	(3,846)	754
Treasury shares	(568)	(568)
Other components of equity	74,662	77,583
Equity attributable to owners of parent	161,668	169,314
Non-controlling interests	(788)	(846)
Total equity	160,880	168,468
Total liabilities and equity	542,510	543,077

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income

(Condensed quarterly consolidated statement of profit or loss)

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Revenue	83,856	90,672
Cost of sales	45,063	46,873
Gross profit	38,792	43,799
Selling, general and administrative expenses	34,962	34,020
Other income	276	813
Other expenses	254	150
Share of profit (loss) of investments accounted for using equity method	(8)	(28)
Operating profit	3,843	10,413
Finance income	45	122
Finance costs	5,879	2,402
Profit (loss) before taxes	(1,990)	8,133
Income tax expense	483	1,839
Profit (loss)	(2,474)	6,293
Profit (loss) attributable to		
Owners of parent	(2,341)	6,338
Non-controlling interests	(133)	(44)
Earnings (loss) per share		
Basic earnings (loss) per share (Unit: JPY)	(18.55)	50.06
Diluted earnings (loss) per share (Unit: JPY)	(18.55)	49.84

(Condensed quarterly consolidated statement of comprehensive income)

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit (loss)	(2,474)	6,293
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit plans	188	917
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(1,942)	(389)
Items that may be reclassified to profit or loss		
Effective portion of cash flow hedges	(80)	—
Exchange differences on translation of foreign operations	3,082	3,348
Share of other comprehensive income of investments accounted for using equity method	(102)	(50)
Other comprehensive income, net of taxes	1,144	3,825
Comprehensive income	(1,330)	10,119
Comprehensive income attributable to		
Owners of parent	(1,193)	10,177
Non-controlling interests	(136)	(57)
Comprehensive income	(1,330)	10,119

(3) Condensed quarterly consolidated statement of changes in equity

(Unit: million yen)

	Equity attributable to owners of parent						
					Other components of equity		
	Share capital	Capital surplus	Retained earnings	Treasury shares	Remeasurements of defined benefit plans	Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	Effective portion of cash flow hedges
As of April 1, 2025	48,623	42,039	2,991	(568)	—	(233)	(17)
Comprehensive income							
Profit (loss)	—	—	(2,341)	—	—	—	—
Other comprehensive income	—	—	—	—	188	(1,942)	(80)
Total comprehensive income	—	—	(2,341)	—	188	(1,942)	(80)
Issuance of new shares	158	174	—	—	—	—	—
Purchase of treasury shares	—	—	—	—	—	—	—
Dividends to owners of parent	—	—	(2,650)	—	—	—	—
Forfeiture of share acquisition rights and Restricted Stock Unit	—	(39)	37	—	—	—	—
Share-based payment transactions	—	(229)	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	188	—	(188)	—	—
Other	—	—	2	—	—	—	—
Transactions with owners	158	(93)	(2,422)	—	(188)	—	—
As of June 30, 2025	48,781	41,946	(1,773)	(568)	—	(2,175)	(98)

(Unit: million yen)

	Equity attributable to owners of parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Share of other comprehensive income of investments accounted for using equity method	Total	Total	Non-controlling interests	Total
As of April 1, 2025	48,447	357	48,553	141,639	(468)	141,171
Comprehensive income						
Profit (loss)	—	—	—	(2,341)	(133)	(2,474)
Other comprehensive income	3,085	(102)	1,148	1,148	(3)	1,144
Total comprehensive income	3,085	(102)	1,148	(1,193)	(136)	(1,330)
Issuance of new shares	—	—	—	332	—	332
Purchase of treasury shares	—	—	—	—	—	—
Dividends to owners of parent	—	—	—	(2,650)	—	(2,650)
Forfeiture of share acquisition rights and Restricted Stock Unit	—	—	—	(2)	—	(2)
Share-based payment transactions	—	—	—	(229)	—	(229)
Transfer from other components of equity to retained earnings	—	—	(188)	—	—	—
Other	—	—	—	2	—	2
Transactions with owners	—	—	(188)	(2,546)	—	(2,546)
As of June 30, 2025	51,533	254	49,514	137,900	(604)	137,295

(Unit: million yen)

	Equity attributable to owners of parent						
					Other components of equity		
	Share capital	Capital surplus	Retained earnings	Treasury shares	Remeasurements of defined benefit plans	Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	Effective portion of cash flow hedges
As of April 1, 2026	48,785	42,636	(3,846)	(568)	—	(701)	—
Comprehensive income							
Profit (loss)	—	—	6,338	—	—	—	—
Other comprehensive income	—	—	—	—	917	(389)	—
Total comprehensive income	—	—	6,338	—	917	(389)	—
Issuance of new shares	329	274	—	—	—	—	—
Purchase of treasury shares	—	—	—	(0)	—	—	—
Dividends to owners of parent	—	—	(2,656)	—	—	—	—
Forfeiture of share acquisition rights and Restricted Stock Unit	—	(17)	1	—	—	—	—
Share-based payment transactions	—	(461)	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	917	—	(917)	—	—
Other	—	—	0	—	—	—	—
Transactions with owners	329	(205)	(1,737)	(0)	(917)	—	—
As of June 30, 2026	49,114	42,430	754	(568)	—	(1,091)	—

(Unit: million yen)

	Equity attributable to owners of parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Share of other comprehensive income of investments accounted for using equity method	Total	Total	Non-controlling interests	Total
As of April 1, 2026	75,387	(23)	74,662	161,668	(788)	160,880
Comprehensive income						
Profit (loss)	—	—	—	6,338	(44)	6,293
Other comprehensive income	3,361	(50)	3,838	3,838	(13)	3,825
Total comprehensive income	3,361	(50)	3,838	10,177	(57)	10,119
Issuance of new shares	—	—	—	603	—	603
Purchase of treasury shares	—	—	—	(0)	—	(0)
Dividends to owners of parent	—	—	—	(2,656)	—	(2,656)
Forfeiture of share acquisition rights and Restricted Stock Unit	—	—	—	(15)	—	(15)
Share-based payment transactions	—	—	—	(461)	—	(461)
Transfer from other components of equity to retained earnings	—	—	(917)	—	—	—
Other	—	—	—	0	—	0
Transactions with owners	—	—	(917)	(2,531)	—	(2,531)
As of June 30, 2026	78,749	(74)	77,583	169,314	(846)	168,468

(4) Condensed quarterly consolidated statement of cash flows

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before taxes	(1,990)	8,133
Depreciation and amortization	6,661	6,691
Interest expenses	1,466	1,767
Decrease (increase) in trade receivables	8,007	4,500
Decrease (increase) in inventories	(4,037)	(1,472)
Increase (decrease) in trade payables	(3,294)	(4,821)
Other	3,043	1,981
Subtotal	9,855	16,780
Interest and dividends received	44	114
Interest paid	(1,375)	(1,441)
Income taxes paid	(3,150)	(1,122)
Income taxes refund	10	0
Net cash provided by operating activities	5,383	14,331
Cash flows from investing activities		
Purchase of property, plant and equipment, and intangible assets	(2,241)	(2,727)
Proceeds from sales of property, plant and equipment, and intangible assets	198	30
Other	(22)	(616)
Net cash used in investing activities	(2,065)	(3,313)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	336	7
Repayments of long-term borrowings	(6,893)	(5,958)
Repayments of lease liabilities	(1,517)	(1,592)
Dividends paid to owners of parent	(2,462)	(2,490)
Other	(10)	14
Net cash used in financing activities	(10,546)	(10,018)
Effect of exchange rate changes on cash and cash equivalents	2,467	461
Net increase (decrease) in cash and cash equivalents	(4,759)	1,462
Beginning balance of cash and cash equivalents	39,592	39,820
Ending balance of cash and cash equivalents	34,833	41,282

(5) Notes to condensed quarterly consolidated financial statements

Notes for going concern

Not applicable

Segment information

1) Reportable segments

Major business contents in each reportable segment are as follows:

Reportable segments	Major business contents
Diabetes Management	Development, manufacturing, and sales of blood glucose monitoring (BGM) systems
Healthcare Solutions	Development of clinical testing business, development and sales of medical IT products such as medical-receipt computers and electronic medical record systems, and development of drug discovery support business
Diagnostics & Life Sciences	Development, manufacturing, and sales of pathological diagnosis equipment, research and medical support equipment, diagnostic reagents and instruments, as well as motorized drug injection devices

(Note) PHC Holdings and its subsidiaries (hereinafter "the Group") has changed the composition of its reportable segments from the fiscal year ending March 31, 2027. The B-to-B business in Indonesia, which was previously included in “Others” has been transferred to “Diagnostics & Life Sciences.” Accordingly, the Group has restated the previously reported segment information for the fiscal year ended March 31, 2026 to reflect this change.

2) Segment revenues and operating results

Three months ended June 30, 2025

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Subtotal	Others, adjustments and eliminations	Consolidated basis
Revenue						
Sale from external customers	23,137	30,474	30,177	83,789	66	83,856
Intersegment sales	—	—	—	—	—	—
Total	23,137	30,474	30,177	83,789	66	83,856
Operating profit (loss)	3,953	860	871	5,685	(1,842)	3,843
Financial income						45
Financial costs						5,879
Profit (loss) before taxes						(1,990)
Other items						
Depreciation and Amortization	1,090	2,632	2,786	6,508	152	6,661
Impairment losses	—	—	1	1	—	1

(Notes) "Others" of "Others, adjustments and eliminations" is an operating segment not included in reportable segments and "adjustments and eliminations" mainly includes eliminations of intersegment transactions and corporate expenses not allocated to each reportable segment.

Three months ended June 30, 2026

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Subtotal	Others, adjustments and eliminations	Consolidated basis
Revenue						
Sale from external customers	27,814	30,976	31,797	90,589	82	90,672
Intersegment sales	—	—	—	—	—	—
Total	27,814	30,976	31,797	90,589	82	90,672
Operating profit (loss)	9,180	1,097	1,813	12,091	(1,678)	10,413
Financial income						122
Financial costs						2,402
Profit (loss) before taxes						8,133
Other items						
Depreciation and Amortization	1,144	2,481	2,875	6,500	191	6,691
Impairment losses (reversal of impairment losses)	(28)	—	—	(28)	—	(28)

(Notes) "Others" of "Others, adjustments and eliminations" is an operating segment not included in reportable segments and "adjustments and eliminations" mainly includes eliminations of intersegment transactions and corporate expenses not allocated to each reportable segment.

Revenue

Disaggregation of revenue

Revenue disaggregation by reportable segments and major regions is as follows.

The Group has changed its composition of reportable segments (please refer to “Segment information”). Accordingly, the Group has restated revenue disaggregation by reportable segments and major regions previously reported for the three months ended June 30, 2025.

Three months ended June 30, 2025

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Other	Total
By region					
Japan	898	30,261	4,466	66	35,693
Europe	12,822	109	7,939	—	20,871
North America	5,318	7	12,618	—	17,943
Other	4,098	96	5,152	—	9,347
Total	23,137	30,474	30,177	66	83,856

Three months ended June 30, 2026

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Other	Total
By region					
Japan	935	30,650	4,261	82	35,930
Europe	16,355	28	8,269	—	24,653
North America	5,646	6	13,290	—	18,943
Other	4,877	289	5,977	—	11,144
Total	27,814	30,976	31,797	82	90,672